FRANKFURT, May 29 (Reuters) - Bayer BAYGn.DE struck a collaboration deal with Roche's ROG.S Foundation Medicine Inc. to develop test kits for genetic sequencing of tumour cells to identify cancer patients that benefit from Bayer's Vitrakvi drug.
Vitrakvi, which Bayer acquired from Eli Lilly's LLY.N Loxo Oncology, has been shown to shrink tumours in about 1 percent of patients across a range 24 different cancer types. Identifying those patients requires advanced genetic diagnostic tools.
(Reporting by Ludwig Burger Editing by Thomas Seythal)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.